🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients

RecruitingNAAges 18 Years - 80 YearsMaleIRCCS Sacro Cuore Don Calabria di Negrar
NCT05884632 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a monoinstitutional prospective pilot study, aiming to evaluate treatment-related toxicity of an hypofractionated postoperative salvage radiotherapy with daily-adaptive modality in patients affected by prostate cancer biochemical recurrence. Patients will be treated with postoperative hypofractionated salvage radiotherapy with a dose of 59 Gy in 20 fractions with daily-adaptive modality. Considering the consolidate role and clinical outcome of postoperative hypofractionated radiotherapy with elevate level of evidence (8-10), the study will not be controlled, but compared with literature data.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≤ 80 years; * Prostate cancer diagnosis, pT2-3 pN0, any resection margin (R0 or R1); * Indication to local salvage treatment defined as: early salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA \<0.2 ng/ml or salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA ≥0.2 ng/ml; * No distant metastases (M0) diagnosed with PSMA-PET-CT; * Informed consent to trial's participation and personal data treatment. Exclusion Criteria: * Age \<18 years old; * Adjuvant radiotherapy; * Previous radiation in the same anatomical site.
💊

What it tests

  • Daily Adaptive RadioTherapy
📍

Where

1 site
IRCCS Sacro Cuore Don Calabria di Negrar
Negrar, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy